Image

Geniculate Artery Embolization for Treatment of Persistent Knee Pain Post Total Knee Arthroplasty

Recruiting
30 - 85 years of age
Both
Phase N/A

Powered by AI

Overview

Single-arm, single-center, no sham or placebo, prospective pilot trial designed to evaluate the safety and efficacy of transcatheter arterial embolization in patients with persistent knee pain resistant to conservative management for at least 9 months after total knee arthroplasty (TKA). Eligible participants will receive geniculate artery embolization (GAE) using Embozene™ Color-Advanced Microspheres. Patients will be followed up for a total of 24 months after GAE.

Eligibility

Inclusion Criteria:

  • Knee pain resistant to conservative treatment for at least 9 months post TKA performed for knee OA, and
  • Moderate to severe knee pain: pain VAS ≥40 mm, and
  • Willing, able, and mentally competent to provide informed consent and complete study questionnaires in English. The Study questionnaires are validated in English.

Exclusion Criteria:

  • Active systemic or local knee infection or;
  • Active malignancy or;
  • Life expectancy less than 6 months or;
  • Prior ipsilateral knee arthroscopic surgery or repeat TKA (within 9 months of screening) or;
  • Ipsilateral knee intra-articular injection in the last 3 months or;
  • Rheumatoid arthritis, spondyloarthropathies, crystal disease, gout, pseudogout, or lupus or;
  • Pregnant during the study period or;
  • Renal dysfunction as defined by serum creatinine >1.6 dl/mg or eGFR <60 on blood tests obtained within 30 days of procedure or;
  • Body weight greater than 200 Kg or;
  • Known history of severe contrast allergy to iodinated contrast resulting in anaphylaxis or;
  • Known significant arterial atherosclerosis that would limit selective angiography and/or lower extremity symptoms thought to be secondary to arterial vascular disease (eg claudication, ischemic rest pain) or;
  • known avascular necrosis in the target knee or;
  • Complications of TKA such as suspected or confirmed early loosening, ligamentous instability, reflex sympathetic dystrophy, polyethylene wear with or without particle disease (osteolysis), and large effusions (with or without hemarthrosis) or;
  • Patient is enrolled in a different trial for treatment of knee pain post total knee arthroplasty (ipsilateral knee)

Study details

Knee Pain

NCT06134817

NYU Langone Health

15 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.